SWP
ALXN

Stratos Wealth Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Stratos Wealth Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,080
Closed -$750K – 1260
2021
Q2 		$750K Sell
4,080
-49
-1% -$8.41K 0.02% 637
2021
Q1 		$631K Sell
4,129
-304
-7% -$47K 0.02% 638
2020
Q4 		$693K Sell
4,433
-438
-9% -$56.3K 0.02% 562
2020
Q3 		$557K Buy
4,871
+288
+6% +$31.1K 0.02% 589
2020
Q2 		$514K Buy
4,583
+1,235
+37% +$131K 0.02% 583
2020
Q1 		$301K Buy
3,348
+1,158
+53% +$114K 0.01% 692
2019
Q4 		$237K Buy
+2,190
New +$234K 0.01% 849
2018
Q2 		– Sell
-1,655
Closed -$184K – 2869
2018
Q1 		$184K Buy
1,655
+307
+23% +$36.7K 0.01% 938
2017
Q4 		$161K Sell
1,348
-1,609
-54% -$196K 0.01% 967
2017
Q3 		$415K Buy
+2,957
New +$402K 0.02% 562

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Stratos Wealth Partners's ALXN Position: Q3 2021 in Review

Stratos Wealth Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4,080 shares — an estimated $750K sold.

Stratos Wealth Partners first reported a position in ALXN in Q3 2017 and held it in 10 quarters. The position peaked at $750K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Stratos Wealth Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Stratos Wealth Partners sold 4,080 Alexion Pharmaceuticals shares in Q3 2021, an estimated $750K.
  • Stratos Wealth Partners first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 10 quarters.
  • Stratos Wealth Partners's Alexion Pharmaceuticals position peaked at $750K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Stratos Wealth Partners's 13F filing for Q3 2021, filed 19 Oct 2021.